<DOC>
	<DOC>NCT00718679</DOC>
	<brief_summary>This study is placebo controlled, double blind, randomised, two arm dose escalation of a new product for specific immunotherapy in cat allergic patients</brief_summary>
	<brief_title>Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria: History and subjective symptoms of cat dander allergy including cat specific allergic rhinitis Age 18 to 65 years Positive reaction to at least one concentration of cat dander allergen in skin prick test, intradermal provocation test and nasal provocation test Exclusion criteria: Chronic infectious disease Acute infections Episode of nonallergic rhinitis within the last 4 weeks Use of allergen known to predict anaphylactic reactions Treatment with any other investigational drug within 3 months before trial entry Vaccination within the last week Nasal surgery within the last 8 weeks Progressive fatal disease Drug or alcohol abuse within the last 5 years Cat ownership A history of significant cardiac insufficiency (NYHA stage IIIIV) Coexisting severe disease, e.g. cardiovascular diseases Acute or history of obstructive respiratory insufficiency ( FEV1 &lt;70%) Hepatic insufficiency Relevant anaemia (as judged by investigator) Blood donation within the last 30 days or intended blood donation (during the study or 30 days after participation) Pregnancy or breast feeding Sexually active woman of childbearing potential not actively practicing birth control by using a medically accepted device or therapy Lack of compliance or other sililar reason, that the investigator believes, precludes satisfactory participation in the study Systemic glucocorticoid therapy Allergic asthma and chronic medication with steroids at doses exceeding 200ug/day Treatment with ATII antagonists, Bblocker, ACE inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>